Advanced Filters
noise
Found 1,144 clinical trials
M Meiqi Yan, Master

Study on iTBS Regulating the Reward Circuit Function to Improve Anhedonia in Depression

The goal of this clinical trial is to learn if the proposed intermittent theta burst stimulation (iTBS) protocol can effectively improve anhedonia symptoms in depressed patients. The stimulation targets in our protocol include (1) dual-target stimulation at the left dorsolateral prefrontal cortex (DLPFC) and orbitofrontal cortex (OFC). (2) single-target stimulation …

18 - 45 years of age All Phase N/A

GynMDD Add-On to Supportive Psychotherapy in Mild to Moderate Depression

The goal of this clinical trial is to learn whether the dietary supplement GynMDD, when taken as an add-on to supportive psychotherapy, can improve symptoms of mild to moderate depression in adults aged 18 to 65. The main questions it aims to answer are: Does adding GynMDD to supportive psychotherapy …

18 - 65 years of age All Phase N/A
M Mattias Damberg, MD, Associate Professor

Behavioral Activation for the Treatment of Depression in Older Adults

Depression affects between 5-15% of adults ≥ 65 years in Sweden. Depression in older adults reduces functional ability and quality of life, and increases the risk for morbidity, loneliness, and suicide. Psychological treatment is recommended as a first-line treatment for depression, which about 3% of older adults with depression in …

65 years of age All Phase N/A
M Mostafa M Bahaa, PhD

Allopurinol in Depression

Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with …

18 - 60 years of age All Phase 2/3
R Robert W Motl, PhD

Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 years of age. The …

18 - 64 years of age All Phase N/A
S Sara Tremblay, PhD

Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression

In this triple-blind randomized controlled trial, we ask if targeting intermittent theta burst stimulation (iTBS) based on individual resting state connectivity improves treatment outcomes in major depressive disorder (MDD). For the trial, we will recruit 210 patients with major depressive disorder. Each patient will undergo a 30-40-minute MRI scan, after …

18 years of age All Phase N/A
I Ilka Mueller, M.Sc.

Effectiveness of an Ecological Momentary Emotion Regulation Intervention

This two-armed randomized controlled trial aims to investigate the effectiveness of an emotion regulation intervention in individuals with and without depressive disorders. The study encompasses participants diagnosed with mild to moderate major depression or persistent depressive disorder and healthy controls without a current depressive disorder. Participants will be randomly assigned …

18 - 65 years of age All Phase N/A
Z Zhou Xinyu, Doctor of Philosophy

Digital Cognitive Behavioral Therapy for Chinese Adolescents With Depressive Symptoms(CADS-D )

CADS-D aimes to evaluate the effectiveness and feasibility of a newly DCBT program for Chinese adolescents with depressive symptoms.

12 - 18 years of age All Phase N/A
A Anissa Megzari

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

Up to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approved for individuals with both AUD and depression. …

18 years of age All Phase 3
H Hillary Jackson

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.

18 - 85 years of age All Phase 0

Simplify language using AI